Cornelia R Bellamacina

US Patent:

7369946, May 6, 2008

Filed:

Mar 22, 2001

Appl. No.:

09/815341

Inventors:

Nancy J. Bump - Lowell MA, US
Lee D. Arnold - Westborough MA, US
Richard W. Dixon - Jefferson MA, US
Hans Wolfgang Hoeffken - Ludwigshafen, DE
Karen Allen - Weston MA, US
Cornelia Bellamacina - Dedham MA, US

Assignee:

Abbott GmbH & Co. KG - Wiesbaden

International Classification:

G06F 19/00

US Classification:

702 27, 702 19, 435 71, 435 692, 435183

Abstract:

The present invention relates to polypeptides which comprise the ligand binding domain of Tie-2, crystalline forms of these polypeptides and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Tie-2. The invention also relates to the use of the three dimensional structure of the Tie-2 catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential inhibitors of Tie-2 activity, for example, compounds which inhibit the binding of a native substrate to the Tie-2 catalytic domain.

US Patent:

20070027150, Feb 1, 2007

Filed:

Apr 14, 2006

Appl. No.:

11/404372

Inventors:

Cornelia Bellamacina - Castro Valley CA, US
Abran Costales - El Cerrito CA, US
Brandon Doughan - Eugene OR, US
Susan Fong - Richmond CA, US
Zhenhai Gao - Hercules CA, US
Thomas Hendrickson - Encinitas CA, US
Barry Levine - Lafayette CA, US
Xiaodong Lin - Walnut Creek CA, US
Timothy Machajewski - Martinez CA, US
Christopher McBride - Oakland CA, US
Maureen McKenna - Pinole CA, US
Kris Mendenhall - Concord CA, US
Alice Rico - Castro Valley CA, US
Cynthia Shafer - Moraga CA, US
Yi Xia - Foster City CA, US
Yasheen Zhou - Moraga CA, US

International Classification:

A61K 31/5377
A61K 31/517
C07D 413/02
C07D 403/02

US Classification:

514234200, 544123000, 544284000, 514252170, 514255050, 514266200, 514266220

Abstract:

2-Amino-quinazolin-5-one compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cell proliferative diseases.

US Patent:

20140249135, Sep 4, 2014

Filed:

May 9, 2014

Appl. No.:

14/273595

Inventors:

Matthew Burger - Emeryville CA, US
Mika Lindvall - Oakland CA, US
Wooseok Han - San Ramon CA, US
Jiong Lan - Shanghai, CN
Gisele Nishiguchi - Emeryville CA, US
Cynthia Shafer - El Sobrante CA, US
Cornelia Bellamacina - Emeryville CA, US
Kay Huh - Emeryville CA, US
Gordana Atallah - Emeryville CA, US
Christopher McBride - San Diego CA, US
William Antonios-McCrea, JR. - Moraga CA, US
Tatiana Zavorotinskaya - Emeryville CA, US
Annette Walter - Mill Valley CA, US
Pablo Dominguez Garcia - Emeryville CA, US

Assignee:

NOVARTIS AG - Basel

International Classification:

C07D 401/12
A61K 31/55
A61K 31/497
A61K 31/4545
A61K 31/444
C07D 491/113
C07D 403/12
A61K 31/506
C07D 241/28
C07D 401/14
C07D 405/14
C07D 409/14
C07D 417/14
C07D 497/04
C07D 403/14
A61K 31/553

US Classification:

51421115, 51421704, 51425505, 514274, 514318, 514332, 514333, 514334, 540481, 540544, 540597, 544230, 544295, 544317, 544405, 546193, 546194, 546262

Abstract:

New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.